TORNTPHARM4,925.00

Torrent Pharmaceuticals Ltd.

· Pharma & Health
AnnualQuarterly₹ CrorePeersSUNPHARMAJBCHEPHARMMANKINDZYDUSLIFEDIVISLABMAXHEALTHDRREDDYCIPLAMcap ₹1.67L Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue from Operations10,728.011,516.013,980.015,723.0
Other Income58.023.0-94.0-69.0
Total Income10,786.011,539.013,886.015,654.0
Expenses
+ Cost of Materials Consumed1,657.01,520.01,758.01,971.0
+ Purchases of Stock-in-Trade1,184.01,531.01,619.01,812.0
+ Changes in Inventories-155.0-275.011.0-6.0
+ Employee Benefit Expense1,984.02,203.02,671.02,959.0
+ Finance Costs354.0252.0385.0634.0
+ Depreciation & Amortisation808.0795.01,119.01,511.0
+ Other Expenses2,690.02,816.03,362.03,796.0
Total Expenses8,522.08,842.010,925.012,677.0
EBITDA3,368.03,721.04,559.05,191.0
EBIT2,560.02,926.03,440.03,680.0
Profit
PBT before Exceptional Items2,264.02,697.02,961.02,977.0
+ Exceptional Items88.0-24.0-89.0-110.0
Pretax Income2,352.02,673.02,872.02,867.0
+ Current Tax462.0619.0844.0897.0
+ Deferred Tax234.0143.0-110.0-186.0
Tax Expense696.0762.0734.0711.0
Net Income1,656.01,911.02,138.02,156.0
+ Net Income — Continuing Ops1,656.01,911.02,138.02,156.0
+ Other Comprehensive Income17.0-93.0-180.0-99.0
Total Comprehensive Income1,673.01,818.01,958.02,057.0
Net Income to Common1,656.01,911.02,163.02,181.0
Minority Interest0.00.0-25.0-25.0
Per Share
Basic EPS48.9456.4763.9262.60
Diluted EPS48.9456.4763.9262.60
Other Comprehensive Income — detail
+ Other Comprehensive Income-93.0-180.0-99.0
+ Items NOT to be Reclassified to P&L-13.0-28.00.0-8.0
+ Tax on Items NOT to be Reclassified-6.00.0-2.0
+ Tax on Items NOT to be Reclassified — alt tag-4.0
+ Items to be Reclassified to P&L46.0-78.0-228.0-107.0
+ Tax on Items to be Reclassified-7.0-48.0-14.0
+ Tax on Items to be Reclassified — alt tag20.0
Comprehensive Income — Owners of Parent1,673.01,818.01,982.02,081.0
Comprehensive Income — Non-controlling Interests0.00.0-24.0-24.0
Per Share — as-filed variants
Basic EPS — Continuing Operations48.9456.4763.9262.60
Diluted EPS — Continuing Operations48.9456.4763.9262.60
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit8,042.08,740.010,592.011,946.0
Gross Margin %74.9675.8975.7775.98
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)2,264.02,697.02,961.02,977.0
− Exceptional Items (reconciliation)88.0-24.0-89.0-110.0
Net Income Adj (tax-effected)1,594.01,928.22,204.32,238.7
EPS Adj47.1156.9865.9065.00
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value5.005.005.005.00
Filed Debt Equity0.00
Filed Dscr0.04
Filed Iscr0.12
Paid Up Equity Capital169.2169.2169.2169.2
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.